Den här översättningen är inte klar ännu. Den här sidan är just nu på engelska.

Gå till den engelska sidan

Cure My Disease

Don't miss your cure!

 Log in / Sign up

New transplant recipe may tame severe anemia

NCT ID NCT06837987

Disease control Sponsor: Hematology department of the 920th hospital Source: ClinicalTrials.gov ↗

What the study statuses mean

This study's is highlighted.

Recruitment status, easiest to join first

Recruiting now
This trial is taking on new participants right now.
Not yet recruiting
Registered, but not yet taking participants.
By invitation only
Not open to general applications. Only people the study team invites can take part.
Paused
Paused for now. It may or may not start again.
Ongoing
Running, but no longer taking on new participants.
Completed This study
The trial has finished. Results may not be published yet.
Stopped early
Stopped early, before it reached the end. That can be for many reasons, including safety.
Cancelled
Cancelled before anyone took part.

Expanded access (not trials)

Expanded access
Not a trial. This treatment can be requested outside a study, case by case, for people who qualify.
Expanded access (paused)
Not a trial. The treatment can normally be requested outside a study, but is unavailable right now.
Expanded access (ended)
Not a trial. The treatment could once be requested outside a study, but no longer can.
Approved
The treatment has been approved, so it is available normally rather than through this programme.

When the status isn't known

Details not published
The full record has not been published yet, so there is little to show here.
Status unknown
This status has not been confirmed recently, so it may be out of date.

First seen Jun 26, 2026 · Last updated Jun 26, 2026

Summary

This study reviews a modified transplant conditioning regimen for severe aplastic anemia in 72 patients across two hospitals. The approach uses a combination of fludarabine, melphalan, and cyclophosphamide to prepare the body for a stem cell transplant. Researchers looked at how well the transplant took and how many patients developed graft-versus-host disease, a common complication.

What this could mean

Our plain-language read of the trial. This is informational only, not medical advice or a prediction.

Active substance
modified transplantation conditioning (fludarabine, melphalan, cyclophosphamide)
What this could lead to
If successful, this modified transplant approach could offer a safer and more effective way to treat severe aplastic anemia, reducing complications like graft failure and graft-versus-host disease.
What could go wrong
This is a small, retrospective study with no control group, so results may not apply to all patients. Transplant procedures carry risks such as infection, organ damage, and graft failure.

This is an AI summary of the original study and may miss details. Read our disclaimer.

Study facts

What this study's own registry entry says, in plain language.

Participants

72 people

The number who actually took part.

Started

Jun 2020

Finished

Aug 2025

Lead sponsor

Other sponsor

The registry's catch-all category, for sponsors it does not file as a company, a government agency, or a research network.

Who can take part

This study's own entry requirements. Only the study team can say for certain whether you qualify.

Who is studied

Patients who were diagnosed with severe aplastic anemia by NCCN guidelines, and has received HSCT with this transplantation preconditioning and aGVHD prophylaxis regimen;

Ages

3 to 65 years

Sex

Anyone

Healthy volunteers

Not accepted

This study is not open to healthy volunteers. The entry requirements below say who it is open to.

Show the full entry requirements

Copied word for word from the study's registry entry, so the wording is the study team's rather than ours.

Inclusion Criteria: 1. Patients who were diagnosed with severe aplastic anemia by NCCN guidelines, and has received HSCT with this transplantation preconditioning and aGVHD prophylaxis regimen; 2. Age 3-65 years old; 3. Weight 10Kg-100Kg; 4. Eastern Cooperative Oncology Group (ECOG) score ≤3; 5. No major organ injury (ECG ejection fraction \>45%; bilirubin \< 2 times the upper limit of normal value; AST and ALT \< 3 times the upper limit of normal value; serum creatinine \< 2 times the upper limit of normal value); 6. No severe infection; 7. Subjects voluntarily participated in this clinical trial and signed the informed consent. Exclusion Criteria: 1. Patients with other hematologic diseases who are not eligible for transplantation or who do not wish to receive transplantation; 2. Patients with an expected survival of less than 1 month; 3. Patients with previous autologous or allogeneic hematopoietic stem cell transplantation; 4. pregnant patients; 5. Patients with severe mental or neurological disorders that would affect the ability to provide informed consent and/or to report or observe adverse events; 6. Other conditions that the investigator determines to be inappropriate for enrollment.

Get updates

Get notified about this study

Sign up to get updates when this study changes or when new studies for Aplastic anaemia are added.

Vår säkerhetsrekommendation!

Genom att skicka in godkänner du våra Användarvillkor

Conditions

The condition(s) this trial relates to.

aplastic anemia idiopathic aplastic anemia

As listed by the trial registrant

The condition terms exactly as the trial's registrant entered them.

Aplastic anaemia Transplantation conditioning

Contacts and locations

Locations

  • Department of Hematology，920th Hospital of Joint Logistics Support Force

    Kunming, Yunnan, 650000, China

More trials for these conditions

Other studies related to the condition(s) this trial covers.